Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. - Wikidata - awgldk - TriplyDB

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

http://www.wikidata.org/entity/Q37338133

about

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive Individuals Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study Challenges in initiating antiretroviral therapy in 2010.Efavirenz in the therapy of HIV infection.Growth among HIV-infected children receiving antiretroviral therapy in Dar es Salaam, Tanzania.Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial.The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.HIV-associated lipodystrophy: a review from a Brazilian perspective The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study The development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settings European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142 Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.High Molecular Weight (HMW): total adiponectin ratio is low in hiv-infected women receiving protease inhibitors.Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection HIV and HAART-Associated Dyslipidemia Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee Lipodystrophy: pathophysiology and advances in treatment Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Switching antiretroviral therapy to minimize metabolic complications.Acquired facial lipoatrophy: pathogenesis and therapeutic options.Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression.A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings Prevalence of and risk factors for lipodystrophy among HIV-infected patients receiving combined antiretroviral treatment in the Asia-Pacific region: results from the TREAT Asia HIV Observational Database (TAHOD).World Health Organization generic protocol to assess drug-resistant HIV among children <18 months of age and newly diagnosed with HIV in resource-limited countries.HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines.Management of the metabolic effects of HIV and HIV drugs.Leptin in relation to the lipodystrophy-associated metabolic syndrome

P2860

Q24628212-6F031EB1-FFF1-496E-817E-AB8ED3157400 Q26768591-24A2C413-CAEB-4D23-95A5-70CC6E9BE981 Q28533379-FBEFA089-6FD2-405E-950E-F6341E0A08BD Q28554250-B21F98D3-F040-4838-B07F-E74108F748BA Q28554630-0108A05C-A26C-43EE-8A00-F90EE8BAABED Q30227046-7E298C37-65C1-4E85-97B4-E76A55A3F105 Q33607011-E7F7CACB-8D2E-4272-A489-50E684B9B871 Q33695680-89847442-E4D4-42EA-BA97-8EC9BC7C03D9 Q33759853-8F2F1901-7988-40BB-ADA0-DE753AB27BFC Q33849136-5F729FF2-FEF5-4520-AAF4-827AF88D4940 Q33939681-E7D33BF0-F7FD-430C-A919-C97469A95D66 Q33985842-A8A4157D-879B-4380-82C9-764CEE1328C6 Q33988391-A1101CD0-6DE8-40AA-AF26-1FE3F0A4D863 Q34039225-8B78B2AA-7C63-4C78-B059-9F2AB53A40CB Q34067682-2D7F09E5-5880-469B-BEEB-6FB068276489 Q34372631-A44E3A1C-E092-4BF2-B23B-4BFFC33FD40A Q34736194-8482F3A5-D1E0-42FF-94B4-28D0DBE3D9CD Q34768650-28C88D92-0C8D-4EA1-977E-895431236981 Q34802246-3B132EEE-B820-4AB1-8E63-A4DA19C60E25 Q34901050-C139691E-CB54-4B16-BBC6-7701D712D077 Q34982530-DEDA7B6C-BEE8-4996-BACA-B2F97F2EA22E Q35001605-BDEC9A73-7D2B-4651-B754-4CFF79F62078 Q35020217-DF0001CF-8986-46B0-82BD-3A34A82DD407 Q35124959-9DFA24A6-19B4-401E-BF3C-6D691A195A33 Q35148915-B21021A7-48DA-4FBB-9996-22742F4865F8 Q35170350-F4FCA257-63FD-438F-A542-FD0761B56620 Q35193326-AB803F24-EC55-4166-B71F-9B2D7B40085B Q35557229-D3D8825C-9EA8-4C7E-9D33-C97D90A568A3 Q35567828-8972C715-C113-4C39-AC27-E288BC1DD85F Q35608074-E448E2DA-9DFA-4A69-BA12-8DA0F0EC57BB Q35620537-89E7E30A-22BB-46C1-B655-39E93759864E Q35871953-557AE572-93A6-4B10-B1A2-DE779BE114DD Q35881469-C8670593-EB86-407C-B495-8CAC5B485A9D Q35898696-69C3B5A3-1FF6-4B1D-BDC5-32C77F1D8BDC Q35917564-C9C050BB-0BAD-4B01-967E-151F7DC6CB0A Q35917583-D7141237-2A7A-4439-9ED1-E96CD88A0C5E Q35939695-CF21C578-13D6-4785-9A79-7223DC2EEFB1 Q36018903-FB5B22C4-59F5-4E21-8295-3A5BD0FAB906 Q36021411-35CD8512-9C56-497A-B8B0-B41EE7564E53 Q36049195-2AE24EDD-9115-4A71-B20B-78FA6E118A30

P2860

Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.

http://www.wikidata.org/entity/Q37338133

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@en

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@nl

type

label

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@en

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@nl

prefLabel

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@en

Metabolic outcomes in a random ...... ens for initial HIV treatment.

@nl

P1433

Q37338133-728249BF-66BA-4B8A-AD62-EC261B7F3E0A

P1476

Q37338133-8C30A062-0123-48EB-A6DA-922B4FA04424

P2093

Q37338133-13E39228-09C9-4FCF-A384-8E7D487B29C0

Q37338133-18C9FE4E-A2EB-4A03-83FA-89583FDDF32D

Q37338133-1E6CCB81-AD1D-4D35-AB10-D5AFD6A97236

Q37338133-2CF8A130-9690-45A9-B36D-796DB22064A5

Q37338133-300A108F-C10F-488F-AFF7-489FD0646BB8

Q37338133-4ADDB7C9-E6CA-4170-A4DA-373E650C938F

Q37338133-4F79682E-0C4B-468E-902D-2CAD45969CE3

Q37338133-5BA0A99F-227C-4124-945A-B20C33E7D20F

Q37338133-77B0CBBC-5977-420A-8746-E29BD635D4C9

Q37338133-B6C8B049-30BF-4C54-9EA2-C69D51ED0BC3

P2860

Q37338133-0CA8D788-9DE1-44FE-83CB-0382C0FD1DA0

Q37338133-28FA734B-069A-4C3A-AFC3-965B79B434FD

Q37338133-3056C8AE-A25C-49A1-8794-6CC8EF650DD4

Q37338133-34F909DC-12E7-429E-8E0F-8DEAC7EA5CA5

Q37338133-378809AE-3FA5-44E3-A9EA-4D9D3DBB8653

Q37338133-3EB42F72-0CE7-4F5F-A336-C9326AB394D0

Q37338133-401D13B8-9388-46EF-B997-563A88F89C4F

Q37338133-42332F35-704F-475F-A4CE-0078CDCC0826

Q37338133-50A47EA7-0B5D-4DDD-BDAD-99C0287390C2

Q37338133-52859216-1533-4B65-A14C-769F0AFE4EE0

P304

Q37338133-111DB7FA-2024-4C91-8E35-2B998316908B

P31

Q37338133-81DA03B6-A566-4B1E-B060-B01ECE57D10E

P356

Q37338133-6786C792-DBA1-4203-AEF9-824A53459F36

P407

Q37338133-7F137E7A-7DCB-486D-B6A5-966A2C447D66

P433

Q37338133-DB472A1A-056C-4FDF-9061-3B1FA1E0D8AA

P478

Q37338133-E0E3473A-0F1B-4B38-9DB7-5CB0D9D69929

P50

Q37338133-447756A1-EA50-4192-9A1E-16310E3FDEDC

Q37338133-D8AD3F1C-4BB7-4294-B6AF-A3F55C8D6D41

P577

Q37338133-2B00E7C3-1F74-484F-85C9-7E98742ACA44

P698

Q37338133-3367D911-E0CF-4642-9B24-6A713B9182C7

P921

Q37338133-7C1067BB-074E-461D-9B7A-EAB17CA48014

P932

Q37338133-17BD96A4-605B-41E8-9022-D93CF55E0CA2

P356

QAD.0B013E32832B4377

P1433

P1476

Metabolic outcomes in a random ...... mens for initial HIV treatment

@en

P2093

A Gregory DiRienzo

http://www.w3.org/2001/XMLSchema#string

AIDS Clinical Trials Group (ACTG) A5142 Study Team

http://www.w3.org/2001/XMLSchema#string

David L Butcher

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

James F Rooney

http://www.w3.org/2001/XMLSchema#string

John W Mellors

http://www.w3.org/2001/XMLSchema#string

Karin Klingman

http://www.w3.org/2001/XMLSchema#string

Kevin W Garren

http://www.w3.org/2001/XMLSchema#string

Lauren Komarow

http://www.w3.org/2001/XMLSchema#string

Richard H Haubrich

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of methods for the measurement of low-density lipoprotein cholesterol.

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management.

Fat distribution in men with HIV infection.

Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.

Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

Redefining lipodystrophy syndrome: risks and impact on clinical decision making.

Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

Class-sparing regimens for initial treatment of HIV-1 infection.

Centralized assessment of dual-energy X-ray absorptiometry (DEXA) in multicenter studies of HIV-associated lipodystrophy.

Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.

P304

1109-1118

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32832B4377

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

William G Powderly

P577

2009-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19417580

http://www.w3.org/2001/XMLSchema#string

P921

P932

2739977

http://www.w3.org/2001/XMLSchema#string